101852-2 |
Fluorometholone |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Fluorometholone [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101852-2 |
|
|
|
|
Both |
|
|
|
0 |
Fluorometholone Ur-sCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; FML Forte Liquifilm; FML Liquifilm; FML S.O.P.; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
101853-0 |
Fluticasone propionate |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Fluticasone propionate [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101853-0 |
|
|
|
|
Both |
|
|
|
0 |
Fluticasone Prop Ur-sCnc |
|
|
|
N |
|
Cutivate; DRUG/TOXICOLOGY; Drugs; Flonase; Flovent; Level; Point in time; Propanoic acid; Propioate; Propioic acid; Propionic acid; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
101854-8 |
Megestrol acetate |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Megestrol acetate [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101854-8 |
|
|
|
|
Both |
|
|
|
0 |
Megestrol Acetate Ur-sCnc |
|
|
|
N |
|
Acetic acid; DRUG/TOXICOLOGY; Drugs; Ethanoate; Ethanoic acid; Level; Megace; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
101855-5 |
Methylprednisolone |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Methylprednisolone [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101855-5 |
|
|
|
|
Both |
|
|
|
0 |
Me-prednisolone Ur-sCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; MeP; Me-prednisolone; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
101856-3 |
prednisoLONE |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
prednisoLONE [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101856-3 |
|
|
|
|
Both |
|
|
|
0 |
prednisoLONE Ur-sCnc |
|
|
|
N |
|
c424; Deltasone; Depo-Medrol; DRUG/TOXICOLOGY; Drugs; Kenalog; Level; Medrol; Point in time; QNT; Quan; Quant; Quantitative; Random; Solu-Medrol; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
101857-1 |
predniSONE |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
predniSONE [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101857-1 |
|
|
|
|
Both |
|
|
|
0 |
predniSONE Ur-sCnc |
|
|
|
N |
|
C254; Cortan; Deltasone; DRUG/TOXICOLOGY; Drugs; Level; Liquid Pred; Meticorten; Orasone; Panasol-S; Point in time; Prednicen-M; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
101858-9 |
Triamcinolone acetonide |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Triamcinolone acetonide [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101858-9 |
|
|
|
|
Both |
|
|
|
0 |
Triamcinolone Aceto Ur-sCnc |
|
|
|
N |
|
Aristocort; Atolone; Azmacort; DRUG/TOXICOLOGY; Drugs; Kenacort; Kenalog; Level; Mycolog II; Nasacort; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
101859-7 |
Triamcinolone |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Triamcinolone [Moles/volume] in Urine |
|
MAJ |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
101859-7 |
|
|
|
|
Both |
|
|
|
0 |
Triamcinolone Ur-sCnc |
|
|
|
N |
|
Aristocort; Atolone; DRUG/TOXICOLOGY; Drugs; Kenacort; Kenalog; Level; Mycolog II; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
10186-5 |
Identifying information |
Find |
^Patient |
Pt |
Nar |
Observed |
|
ACTIVE |
Identifying information Narrative Observed |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10186-5 |
|
Observed |
|
|
|
|
|
|
0 |
Identifying information Observ |
|
|
|
|
|
Finding; Findings; H+P; H+P.HX; Narrative; P prime; Point in time; Random; Report |
2.4 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
101860-5 |
4F-MDMB-BUTICA |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
4F-MDMB-BUTICA [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101860-5 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
4F-MDMB-BUTICA Ur Cfm-mCnc |
|
|
|
N |
|
4F-Mdmb-bica; Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; L-Valine, N-((1-(4-fluorobutyl)-1H-indol-3-yl)carbonyl)-3-methyl-, methyl ester; Mass concentration; Methyl N-{[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}-3-methyl-L-valinate; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
101861-3 |
4F-MDMB-BUTICA/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
4F-MDMB-BUTICA/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
101861-3 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
4F-MDMB-BUTICA/Creat Ur Cfm |
|
|
|
N |
|
4F-Mdmb-bica; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; L-Valine, N-((1-(4-fluorobutyl)-1H-indol-3-yl)carbonyl)-3-methyl-, methyl ester; Mass concentration ratio; Mass ratio; MCRto; Methyl N-{[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}-3-methyl-L-valinate; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
101862-1 |
4F-MDMB-BUTICA |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
4F-MDMB-BUTICA [Presence] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101862-1 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
4F-MDMB-BUTICA Ur Ql Cfm |
|
|
|
N |
|
4F-Mdmb-bica; Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; L-Valine, N-((1-(4-fluorobutyl)-1H-indol-3-yl)carbonyl)-3-methyl-, methyl ester; Methyl N-{[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}-3-methyl-L-valinate; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101863-9 |
Complement factor H Ab |
ACnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Complement factor H Ab [Units/volume] in Serum or Plasma by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
HEM/BC |
|
101863-9 |
|
IA |
|
|
Both |
|
|
|
0 |
Comp Fact H Ab SerPl IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Beta 1 H; Bombay AB; C3b inactivator accelerator; Comp; Comp Fact H; Complmt; EIA; ELFA; ELISA; Enzyme immunoassay; Fac; Fact; HEMATOLOGY/CELL COUNTS; IAA; MEIA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
101864-7 |
Oxygen/Gas.total setting |
VFr |
ECMO device |
Pt |
Qn |
|
|
ACTIVE |
Oxygen/Total gas setting ECMO device |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
PULM |
|
101864-7 |
|
|
|
|
Both |
|
|
|
0 |
O2/Total gas setting VFr ECMO device |
|
|
|
N |
|
Gases; O2; O2/gas .tot set; Percent; Point in time; PULMONARY; QNT; Quan; Quant; Quantitative; Random; tO2; Tot; Total gas setting; Totl; Volfr; Volume fraction |
2.75 |
2.75 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
101865-4 |
Troponin T. cardiac 2H &6H 5th generation panel |
- |
Ser/Plas |
- |
- |
High sensitivity |
|
ACTIVE |
Troponin T. cardiac 2H and 6H 5th generation panel in Serum or Plasma by High sensitivity method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101865-4 |
|
High sensitivity |
|
|
Order |
|
|
|
0 |
Troponin T 2H 6H 5th gen SerPl HS |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; Chemistry; cTnT; HS; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; T prime; TnT; Troponin; Troponin T 2H 6H |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101866-2 |
Gas and electrolytes point of care panel |
- |
BldV |
Pt |
- |
|
|
ACTIVE |
Gas and electrolytes point of care panel - Venous blood |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101866-2 |
|
|
|
|
Order |
|
|
|
0 |
Gas + Electrolytes poc pnl BldV |
|
|
|
N |
|
Bld ven; Bld venous; Blood - venous; Blood gas ven; Blood ven; Blood venus; Chemistry; Elect; Electr; Electrolyte; Gas + Electrolytes poc pnl; Gases; Lytes; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; Random; Venous |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101867-0 |
Ma2 Antibody |
PrThr |
CSF |
Pt |
Ord |
IA |
|
ACTIVE |
Ma2 Antibody [Presence] in Cerebral spinal fluid by Immunoassay |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
101867-0 |
|
IA |
|
|
Both |
|
|
|
0 |
Ma2 Ab CSF Ql IA |
|
|
|
N |
|
Ab; Cerebral spinal fluid; Cerebrospinal Fl; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Ma2 Ab; MEIA; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101868-8 |
Ma2 Antibody |
PrThr |
Ser/Plas |
Pt |
Ord |
IA |
|
ACTIVE |
Ma2 Antibody [Presence] in Serum or Plasma by Immunoassay |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
101868-8 |
|
IA |
|
|
Both |
|
|
|
0 |
Ma2 Ab SerPl Ql IA |
|
|
|
N |
|
Ab; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Ma2 Ab; MEIA; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
10187-3 |
Review of systems |
Find |
^Patient |
Pt |
Nar |
Reported |
|
ACTIVE |
Review of systems Narrative - Reported |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10187-3 |
|
Reported |
|
|
|
|
|
|
0 |
Review of systems |
|
|
|
|
|
Finding; Findings; H+P; H+P.HX; Narrative; P prime; Point in time; Random; Report |
2.63 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
101870-4 |
Gamma aminobutyrate A receptor Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
CBA IFA |
|
ACTIVE |
GABAAR IgG Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
101870-4 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
GABAAR IgG Titr CSF CBA IFA |
|
|
|
N |
|
4-aminobutanoic acid; 4-aminobutyrate; 4-aminobutyric acid; ABS; Aby; Aminobutric; Aminobutyric; Amino-n-butyrate; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); GABA; GABAAR; GABAAR Ab; Gamma aminobutyric acid; Gamma amino-butyric acid; Gamma amino-n-butyrate; Gamma amino-n-butyric acid; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Piperidic acid; Point in time; Random; Rec; Recept; Receptors; Recp; Recptr; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr |
2.76 |
2.75 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
101871-2 |
IgLON family member 5 Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
CBA IFA |
|
ACTIVE |
IgLON5 IgG Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
101871-2 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
IgLON5 IgG Titr CSF CBA IFA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); IgLON5; IgLON5 Ab; IgLON5 IgG; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Point in time; Random; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr |
2.76 |
2.75 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
101872-0 |
Inositol 1,4,5-trisphosphate receptor type 1 Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
CBA IFA |
|
ACTIVE |
Inositol 1,4,5-trisphosphate receptor type 1 IgG Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
101872-0 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
IP3R 1 IgG Titr CSF CBA IFA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Cyclohexane-1,2,3,4,5,6-hexol; Dilution factor; Dilution Factor (Titer); i; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; InsP3R1; IP3 receptor isoform 1; IP3R 1; IP3R 1 Ab; IP3R 1 IgG; ITPR; ITPR1; Point in time; Random; Rec; Recept; Receptors; Recp; Recptr; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr; Type 1 inositol 1,4,5-trisphosphate receptor; Type 1 InsP3 receptor |
2.76 |
2.75 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
101873-8 |
Metabotropic glutamate receptor 1 Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
CBA IFA |
|
ACTIVE |
Metabotropic glutamate receptor 1 IgG Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
101873-8 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
mGluR1 IgG Titr CSF CBA IFA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; c707; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); Glu; Glutamic acid; i; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; mGluR1; mGluR1 Ab; mGluR1 IgG; Point in time; Random; Rec; Recept; Receptors; Recp; Recptr; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr |
2.76 |
2.75 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
101874-6 |
Gamma aminobutyrate A receptor Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
GABAAR IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
101874-6 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
GABAAR IgG Ser Ql CBA IFA |
|
|
|
N |
|
4-aminobutanoic acid; 4-aminobutyrate; 4-aminobutyric acid; ABS; Aby; Aminobutric; Aminobutyric; Amino-n-butyrate; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; GABA; GABAAR; GABAAR Ab; Gamma aminobutyric acid; Gamma amino-butyric acid; Gamma amino-n-butyrate; Gamma amino-n-butyric acid; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Ordinal; Piperidic acid; Point in time; PR; QL; Qual; Qualitative; Random; Rec; Recept; Receptors; Recp; Recptr; Screen; Serology; Serum; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101875-3 |
Gamma aminobutyrate A receptor Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
CBA IFA |
|
ACTIVE |
GABAAR IgG Ab [Titer] in Serum by Cell binding immunofluorescent assay |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
101875-3 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
GABAAR IgG Titr Ser CBA IFA |
|
|
|
N |
|
4-aminobutanoic acid; 4-aminobutyrate; 4-aminobutyric acid; ABS; Aby; Aminobutric; Aminobutyric; Amino-n-butyrate; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); GABA; GABAAR; GABAAR Ab; Gamma aminobutyric acid; Gamma amino-butyric acid; Gamma amino-n-butyrate; Gamma amino-n-butyric acid; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Piperidic acid; Point in time; Random; Rec; Recept; Receptors; Recp; Recptr; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.76 |
2.75 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |